What You Should Know About Ozempic and Gastroparesis in New Jersey
From General Health Information to Targeted Risk Assessment
If you or someone you know has experienced persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be concerned about gastroparesis—a condition where the stomach empties too slowly. Decades of pharmacovigilance research have documented gastrointestinal side effects from GLP-1 receptor agonists, and recent adverse event reports have focused attention on this specific risk. This page reviews the reported cases in New Jersey and explains what the data shows.
Bridging General Knowledge to Ozempic-Specific Risks
Building on the general health framework, it is essential to understand the specific medical and legal landscape surrounding Ozempic and gastroparesis. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for weight management. Among its known risks, gastrointestinal adverse reactions are prominent. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
Gastroparesis: Mechanism and Clinical Evidence
Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy or breath tests. The mechanistic pathways linking Ozempic to gastroparesis involve the drug's action as a GLP-1 receptor agonist, which slows gastric motility and can exacerbate or unmask underlying gastroparesis. While the Ozempic label does not explicitly list gastroparesis as an adverse reaction, it does report related gastrointestinal conditions. In addition to nausea and vomiting, the following gastrointestinal adverse reactions with a frequency of less than 5% were associated with Ozempic (frequencies listed, respectively, as: placebo; 0.5 mg; 1 mg): dyspepsia (1.9%, 3.5%, 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, and the drug's known effect on gastric emptying supports a plausible link.
Adequacy of Warnings and Legal Implications
Regarding the adequacy of warnings, the Ozempic label includes a section on hypersensitivity reactions, noting that serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not specifically warn about gastroparesis as a potential adverse effect. This omission may be relevant for patients who develop gastroparesis symptoms while on Ozempic, as they might not be adequately informed of the risk. The label does caution about gastrointestinal adverse reactions in general, but the absence of a specific gastroparesis warning could be a point of contention in settlement considerations. For affected patients in New Jersey, the statute of limitations for product liability claims, including those related to Ozempic and gastroparesis, is generally two years from the date the injury was discovered or should have been discovered. This timeline is critical because gastroparesis symptoms may develop gradually after starting Ozempic, and the link between the drug and the condition might not be immediately apparent. The timeline between exposure and documented harm is variable; some patients may experience symptoms during dose escalation, while others may develop gastroparesis after months of use. Given that gastrointestinal adverse reactions often occur during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), patients who discontinue Ozempic due to severe nausea or vomiting might later be diagnosed with gastroparesis. The statute of limitations clock typically starts when the patient knows or reasonably should know that the injury was caused by the drug.
Settlement Considerations for Affected Patients
Settlement-related considerations for affected patients include the need to document the timing of Ozempic use, onset of symptoms, and medical diagnosis of gastroparesis. Patients should also consider whether the drug's labeling provided adequate warnings. The absence of a specific gastroparesis warning in the label (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166) may strengthen claims that the manufacturer failed to adequately warn about this risk. However, the label does list gastrointestinal adverse reactions, which could be argued as sufficient warning. Patients in New Jersey should consult with a legal professional to assess their individual circumstances and ensure compliance with the statute of limitations.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Ozempic gastroparesis claims in New Jersey?
In New Jersey, the statute of limitations for product liability claims, including those related to Ozempic and gastroparesis, is generally two years from the date the injury was discovered or should have been discovered. This timeline is critical because gastroparesis symptoms may develop gradually after starting Ozempic, and the link between the drug and the condition might not be immediately apparent. Patients should consult with a legal professional to ensure compliance.
Does the Ozempic label warn about gastroparesis?
The Ozempic label does not explicitly list gastroparesis as an adverse reaction, but it does report related gastrointestinal conditions such as dyspepsia, eructation, flatulence, gastroesophageal reflux disease, and gastritis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The absence of a specific gastroparesis warning may be relevant for patients who develop symptoms while on Ozempic.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.